Skip to content
Donate
Membership
Contact
  • About

    About

    The peak professional body for childhood cancer across Australia and New Zealand.

    Learn More

    Menu

    • About ANZCHOG
    • Board of Directors
    • Our People
    • Our Network
    • Supporters & Partners
    • Position Statements & Guidelines
  • Clinical Trials
    Total Trials
    60
    Open Trials
    26
    Preparing to Open
    3
    Temp. Closed
    3
    Closed
    21
    Complete
    7

    Menu

    • Our Trials
    • Children's Clinical Cancer Clinical Trials Repository
    • Childhood Cancer
  • Resource SPACE
    Document/ PDF

    Supporting parents making clinical trial decisions for their child

    Behavioural Sciences Unit – Delta Study
    Document/ PDF

    Should my child participate in a clinical trial

    Center for Information and Study on Clinical Research Participation (CISCRP)

    Menu

    • Visit SPACE
    • Videos
    • Documents
    • Podcasts
  • Major Projects
    • July 2, 2025

    Getting to know CoACT in Brain Cancer Awareness Month

    • childhoodcancer, clinical trials, Paediatric Brain Cancer
    • February 6, 2025

    Australian Government invests $14 million in ANZCHOG-led childhood brain cancer initiative

    • childhoodcancer, clinical trials, Paediatric Brain Cancer

    Menu

    • CoACT
    • Equitable Pathways
    • CIRCCA
    • Optimal Care Pathways
  • Annual Scientific Meeting

     Innovate, Integrate, Inspire:   Elevating Supportive Care in Paediatric Haematology and Oncology  

    Learn More

    Menu

    • 2026 Newcastle
    • Program
    • Speakers
    • Accommodation
  • News & Events
    • Featured, PaedNeoVax, Trial Update
    • November 5, 2026

    PaedNeoVax Clinical Trial Opens to Target Aggressive Childhood Brain Tumours

    Menu

    • Latest News
    • Upcoming Events

    8–11 September 2027

    SIOP 2027

  • About Us
    • ANZCHOG
    • Board of Directors
    • Our People
    • Our Network
    • Collaborators, Supporters & Partners
  • Clinical Trials
    • Clinical Trials
    • ANZCHOG Children’s Cancer Clinical Trials Repository
    • Childhood Cancer
  • Major Projects
    • CIRCAA
    • CoACT
    • Equitable Pathways
    • Optimal Care Pathways
  • Resource Space
  • Membership
  • Annual Scientific Meeting
Membership
Donate
Contact
Closed to RecruitmentPhase 2

Pαβlo

TCR α+β+/CD19+ cell depleted haploidentical donor stem cell transplantation for paediatric patients

View on registry →Registry IDs: ACTRN12617001174370

Approximately 150 children undergo bone marrow transplant in Australia and New Zealand every year. Some children have stem cells donated from a relative, and others get their stem cells from a volunteer donor who is a genetic match, or from donated umbilical cord blood. Some patients, however, do not have any of these donors available.

Parents share half of their genes with their children, and so are haploidentical (a half genetic match). Haploidentical donors have not been used routinely in the past because of the complication known as graft versus host disease (GVHD). GVHD is when the donor cells attack the patient’s body because they are not a complete genetic match. GVHD is caused by a specific type of blood cell, called a TCR α+β+ T cell. Transplant doctors now have a way of removing these T cells from the donor stem cells, to stop GVHD from occurring. This is called TCR α+β+ cell depletion. The purpose of this study is to take haploidentical donor stem cells, and perform TCR α+β+/CD19+ cell depletion before they are given to a patient. It is hoped that the donor stem cells will grow (engraft) in the patient, and that the chance of the patient getting GVHD will be low, thus improving treatment outcomes for these children.

The primary purpose of this trial is to evaluate the efficacy of using parent donors for bone marrow transplants in children, using a particular processing method of the donor blood cells (TCR a+ß+/CD19+ cell depletion) compared to those receiving a standard bone marrow transplant from another donor, We also want to compare cost to the health system of TCR a+ß+/CD19+ cell depletion with that of standard bone marrow transplant procedures,

Who is it for?
Patients may be eligible to enrol in this trial if they are aged 3 months to 18 years of age, have been diagnosed with haematological malignancies or non malignant disorders requiring a bone marrow transplant, and have an eligible parent donor.

Study details
Patients who have no fully matched brothers or sisters, and no well matched volunteer donors or umbilical cord blood units available will receive a TCR a+ß+/CD19+ cell depleted graft from a parent donor. Control patients will receive a standard bone marrow transplant from another donor (e.g., volunteer donor) as per institutional practice.

Patients will undergo clinical assessments at regular intervals for two years following the transplant to evaluate the efficacy of the treatment. Further information, such as quality of life and carer burden, will be collected for up to 5 years following the transplant.

It is hoped that the findings from this trial will provide information on whether parent donor cells undergoing specialised cell processing can be effectively used for bone marrow transplants in children with haematological malignancies or non malignant disorders.

Site Status
Queensland Children's Hospital (QLD) Closed to Recruitment
Sydney Children's Hospital (NSW) Closed to Recruitment
Royal Children's Hospital (VIC) Closed to Recruitment
Perth Children's Hospital (WA) Closed to Recruitment
Children's Hospital at Westmead (NSW) Closed to Recruitment
Starship Children's Hospital (NZ) Closed to Recruitment
Preparing to openOpenClosedComplete
Diagnosis StageNewly Diagnosed
National SponsorANZCHOG
Open Date06/09/2018
ConditionsBone marrow transplant
Patient RangeUp to < 18 years
05099+
Disease TypeLeukaemia / Lymphoma / Blood Disorders
Study TypeInterventional

Media & Publication Highlights

Last updated 10 November 2026

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

Subscribe to our Newsletter

    • Terms Of Use
    • Privacy Policy
    • Terms Of Use
    • Privacy Policy
    • Resource Hub
    • Childhood Cancer
    • What We Do
    • Resource Hub
    • Childhood Cancer
    • What We Do
    • Our Trials
    • Our Network
    • Position Statements & Guidelines
    • Our Trials
    • Our Network
    • Position Statements & Guidelines

    Email
    info@anzchog.org

    Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

    Copyright © 2026 ANZCHOG - All Rights Reserved

    Linkedin-in